By Linetta Koppert, member of the H2O Initiative and Oncological surgeon, clinical epidemiologist, MD PhD at Erasmus MC responds to new data from ASCO We at H2O welcome the presentation of secondary endpoints from the PRO-TECT study related to patient reported outcomes (PROs) and intervention feasibility. These finding, presented as part of the #ASCOPlenarySeries, demonstrate […]
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 945345-2. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and Trial Nation and JDRF.
The Innovative Medicines Initiative is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). It is working to improve health by speeding up the development of the next generation of medicines, particularly in areas where there is an unmet medical or social need. It works by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. http://www.imi.europa.eu/